Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104)

PURPOSE: Capecitabine plus cisplatin (XP) is a standard therapy for metastatic gastric cancer (mGC). However, while results from previous phase III trials suggested that the cisplatin dosage should be reduced in Japanese patients, no clinical data exist to support this. Here, we conducted a multicen...

Descripción completa

Detalles Bibliográficos
Autores principales: Satake, Hironaga, Iwatsuki, Masaaki, Uenosono, Yoshikazu, Shiraishi, Takeshi, Tanioka, Hiroaki, Saeki, Hiroshi, Sugimachi, Keishi, Kitagawa, Dai, Shimokawa, Mototsugu, Oki, Eiji, Emi, Yasunori, Kakeji, Yoshihiro, Tsuji, Akihito, Akagi, Yoshito, Natsugoe, Shoji, Baba, Hideo, Maehara, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225198/
https://www.ncbi.nlm.nih.gov/pubmed/27942930
http://dx.doi.org/10.1007/s00280-016-3204-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225198/
https://www.ncbi.nlm.nih.gov/pubmed/27942930
http://dx.doi.org/10.1007/s00280-016-3204-6

Ejemplares similares